What is VetDC?
VetDC operates at the intersection of biotechnology and veterinary medicine, specializing in the development of advanced therapeutic solutions for animal oncology. The company is recognized for its focus on translating human medical breakthroughs into practical, life-improving treatments for pets. Its flagship development, TANOVEA-CA1, exemplifies the firm's dedication to addressing canine lymphoma through rigorous clinical standards. By providing veterinarians with specialized tools and novel therapies, VetDC occupies a unique market position that prioritizes both clinical efficacy and the quality of life for animal patients. The company's strategic focus on evidence-based oncology positions it as a leader in the rapidly evolving field of veterinary specialty care.
How much funding has VetDC raised?
VetDC has raised a total of $5.7M across 5 funding rounds:
Private Equity
$1.5M
Private Equity
$1.3M
Grant
$250K
Private Equity
$587K
Private Equity
$2.1M
Private Equity (2012): $1.5M, investors not publicly disclosed
Private Equity (2013): $1.3M, investors not publicly disclosed
Grant (2013): $250K supported by Colorado Office of Economic Development & International Trade
Private Equity (2014): $587K, investors not publicly disclosed
Private Equity (2015): $2.1M, investors not publicly disclosed
Key Investors in VetDC
Colorado Office of Economic Development & International Trade
A state-level agency focused on fostering economic growth and job creation by providing strategic resources and funding support to innovative businesses within Colorado.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for VetDC?
Looking ahead, VetDC is poised to leverage its recent capital influx to accelerate the commercialization of its pipeline and expand its reach within the veterinary oncology market. The strategic roadmap likely includes scaling clinical trials, enhancing distribution networks for its therapeutic portfolio, and deepening its research into novel oncology modalities. As the company matures, it will likely focus on solidifying its market presence through continued collaboration with veterinary specialists and academic institutions. This phase of development is critical for VetDC as it seeks to establish its innovative therapies as the standard of care, ultimately driving long-term value for stakeholders and improving outcomes for companion animals globally.
See full VetDC company page
